The American Academy of Addiction Psychiatry (AAAP) was awarded a $55,500,000 Substance Abuse and Mental Health Services Projects of Regional and National Significance (CFDA 93.243) grant from the Substance Abuse and Mental Health Services Administration (SAMHSA). The funding will support the Opioid Response Network (ORN), a collaborative network that provides training and technical assistance (TTA) to address opioid use disorder, stimulant use disorder, other substance use disorders, and...
The National Institute on Drug Abuse (NIDA) awarded The Washington University a 3-year, $2,337,729 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to study the impact of prenatal opioid exposure on placental and fetal brain development. The project, titled "The Opioid in Pregnancy: Imaging of Oxygenation, Inflammation, and Development in Brain & Placenta" (OPIOID BPP), aims to define the longitudinal effects of prenatal opioid exposure on...
The National Institute on Drug Abuse (NIDA) awarded a $800,000 Cooperative Agreement (CFDA 93.279 - Drug Use and Addiction Research Programs) to Biosensics LLC to develop ODALERT, a wearable device for the automatic detection of opioid-induced respiratory arrest. The key products to be delivered under this funding include: Completing the development of the ODALERT sensor, optimizing the battery, and deploying real-time algorithms for respiratory cessation detection. Securing FDA...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,902,673.00 to Rutgers, The State University of New Jersey to conduct research on establishing OPRM1 exon 7-associated variants as therapeutic targets for mitigating adverse effects of clinically used mu opioids without impacting analgesia. The key objectives are to characterize antisense oligonucleotides (ASOs) and rabbit monoclonal antibodies...
This federal Project Grant award of $459,045 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to modify the Opioid Use Disorder (OUD) Cascade of Care model to better reflect the changing landscape of real-world OUD treatment. The project will link data across healthcare and substance use treatment systems in Los Angeles County to construct a cross-system OUD care cascade, with the ultimate goal of reducing OUD-related...
This federal Project Grant award of $945,966 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is funding research to investigate the potential of targeting the GPR83 receptor as a strategy to reduce the abuse liability of opioid medications while enhancing their analgesic effects. The project aims to unravel the neurobiological mechanisms by which the GPR83 receptor and its endogenous ligand PEN interact with the mu-opioid...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $601,612 to the Icahn School of Medicine at Mount Sinai to conduct research on the habenula-interpeduncular nucleus (IPN) circuit and its role in opioid tolerance and withdrawal. The project aims to use viral approaches, ribosome profiling, and in vivo oxycodone administration in mice to examine gene expression and neuronal calcium dynamics in...
This $451,962 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to address racial disparities in opioid overdose deaths among Black and Latinx people who use opioids (PWUO). The project will: Adapt an evidence-supported Cultural and Structural Humility (CSH) training to an interactive video format for peer recovery coaches (PRCs) to enhance their telephone-based care coordination services for PWUO. Refine an...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,704,286 to Texas A&M University System Health Science Center (TAMU HSC) to conduct research on overcoming opioid-induced respiratory depression (OIRD) in sleep apnea patients. The research aims to uncover the biological basis for why sleep apnea patients are more sensitive to the respiratory depressive effects of opioids, which is...
This $100,000 Project Grant award, provided by the Agency for Healthcare Research and Quality (AHRQ) under the Research on Healthcare Costs, Quality and Outcomes (CFDA 93.226) program, will fund a series of three annual health professions conferences hosted by the Auburn University Harrison College of Pharmacy's Center for Opioid Research, Education, and Outreach (COACH). These conferences, occurring from 2025-2027, will focus on safe opioid prescribing and harm reduction strategies for older...